Kornimate/medical-research-clean huggingface dataset:
characteristics of episodic ataxia syndrome

Conditions: Episodic Ataxia Syndrome; Cerebellar Diseases

Summary: episodic ataxia (ea) is a rare genetic disease characterized by episodes of imbalance, incoordination, and slurring of speech. the underlying cause of ea is only partly understood, and currently there are no established treatments. there is also little information about the link between ea's clinical features and its genetic basis. the purpose of this study is to better characterize ea and disease progression. in turn, this may direct the development of future treatments.

attacks of ataxia, or the loss of ability to coordinate muscular movement, are often triggered by stress or exertion. ea is likely caused by an inherited genetic mutation; many individuals with ea have abnormalities in the kcna1 or cacna1a genes. to date, two known subtypes of ea have been identified, and other types likely exist. specific characteristics of each ea subtype, however, have not been adequately described. the purpose of this study is to better define the clinical features and genetic basis of the various subtypes of ea and to evaluate disease progression. the study will also establish relevant study endpoints for use in future therapeutic trials. this multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. participants will initially attend an outpatient study visit that will last 7 hours. this initial evaluation will include a medical history, a physical examination, neurological testing, and an ataxia assessment. blood will be collected for genetic testing. additionally, the following procedures may be conducted: ocular motor test, electromyography/nerve conduction study, electroencephalogram, mri, and digital videotaping. follow-up evaluations will occur on a yearly basis for at least 2 years; each will last 4 hours.

Eligibility criteria:
inclusion criteria: * a clinically confirmed diagnosis of episodic ataxia as defined by one of the following three features: 1. clear-cut episodes of recurrent, transient ataxia 2. mutation confirmed in kcna1 or cacna1a 3. ataxic features with a first degree relative with episodic ataxia exclusion criteria: * any other disorder known to cause episodic ataxia
efficacy of eltrombopag to improve thrombocytopenia of myh9-related disease

Conditions: Blood Platelet Disorders

Summary: the term myh9-related disease (myh9rd) includes four genetic disorders: may-hegglin anomaly, sebastian syndrome, fechtner syndrome, and epstein syndrome. all these disorders derive from mutation of a unique gene, named myh9, and they have been recognized as different clinical presentations of a single illness that was named myh9rd. all patients affected by myh9rd present since birth with thrombocytopenia, which can result in a variable degree of bleeding diathesis; some of them subsequently develop additional clinical manifestations, such as renal damage, sensorineural hearing loss, and/or presenile cataracts. eltrombopag is an oral thrombopoietin receptor agonist that stimulates proliferation and differentiation of megakaryocytes, the bone marrow cells that produce blood platelets. this drug is effective in increasing platelet count in healthy volunteers, as well as in patients affected by some acquired thrombocytopenias, such as idiopathic thrombocytopenic purpura and hcv related thrombocytopenia. the purpose of this study is to determine if eltrombopag, administered orally at the dose of 50 or 75 mg/daily for up to 6 weeks, is effective in increasing platelet count of patients affected by myh9rd. further aims of this study are to test if eltrombopag is effective in reducing bleeding tendency of myh9rd patients; to evaluate safety and tolerability of eltrombopag in patients with myh9rd; to evaluate in vitro function of platelets produced during therapy in patients responding to this drug.


Eligibility criteria:
inclusion criteria: * age 16 years or more * confirmed diagnosis of myh9-related disease * average platelet count for the previous year less than 50x10e9/l * written informed consent exclusion criteria: * diseases known to involve the risk of thromboembolic events (e.g. atrial fibrillation) * history of thrombosis within 1 year * use of drugs that affect platelet function (including but not limited to, aspirin, clopidogrel or nsaids) or anti-coagulants * females who are pregnant or nursing (a negative pregnancy test in required before enrollment of fertile women) * formal refusal of any recommendation of a safe contraception * alcohol or drug addiction * altered renal function as defined by creatinine of 20 mg/l or more * any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioral problems. hcv positivity and liver diseases will not be considered an exclusion criterion since a phase ii study showed that eltrombopag was effective and safe in this patient population.

Keywords: inherited thrombocytopenia myh9 mutations eltrombopag
surgery combined with maintenance targeted therapy in the treatment of advanced ovarian cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma

Summary: optimal timing of surgery combined with maintenance therapy in the front-line treatment of advanced ovarian cancer

the purpose of this trial is to answer the fundamental question 'the optimal timing of surgery' combined with bevacizumab or poly-adenosine ribose phosphate inhbitors (parpi), in the circumstance of primarily diagnosed advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma.

Eligibility criteria:
inclusion criteria: * females aged ≥ 18 years. * pathologic confirmed stage iiic and iv epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma * low, middle tumor burden and high tumor burden with cpci score ≤ 12 based on pre-operative ct or pet/ct examination * complete cytoreduction can be achieved based on ct or pet/ct examination * patients must agree to undergo brca (breast cancer gene) and hrd (homologous recombination deficiency) testing * performance status (ecog 0-2) * adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery: 1. white blood cells \>3,000/µl, absolute neutrophil count ≥1,500/µl, platelets ≥100,000/µl, hemoglobin ≥9 g/dl, 2. serum creatinine \<1.25 x upper normal limit (unl) or creatinine clearance ≥60 ml/min according to cockroft-gault formula or to local lab measurement, 3. serum bilirubin \<1.25 x unl, ast(sgot) and alt(sgpt) \<2.5 x unl. * comply with the study protocol and follow-up. * patients who have given their written informed consent. exclusion criteria: * non-epithelial ovarian malignancies and borderline tumors * low grade ovarian cancer * mucinous ovarian cancer * complete cytoreduction cannot be achieved according to preoperative evaluation, including pulmonary and hepatic parenchymal metastases, unresectable extensive pleural metastases, multiple thoracic lymph nodes metastases, brain or bone metastases * patient has a known hypersensitivity to the components of olaparib/bevacizumab or its excipients * synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ, thyroid carcinoma, or breast carcinoma (without any signs of relapse or activity, early-stage). * any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise adherence to the protocol. * other conditions, such as religious, psychological, and other factors, that could interfere with the provision of informed consent, compliance to study procedures, or follow-up.

Keywords: ovarian cancer primary debulking surgery neoadjuvant chemotherapy poly-adenosine ribose phosphate inhbitors (parpi) bevacizumab
efficacy, tolerability and safety of nva237 in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study will assess the efficacy, tolerability and safety of nva237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: * patients with moderate to severe copd (stage ii or stage iii) according to the gold 2010 guideline * current or ex-smokers who have a smoking history of at least 10 pack years * qualifying fev1 at visit 2 (day -7) exclusion criteria: * patients with a history of asthma or a history of high blood eosinophil count (\>600/mm³) * patients with concomitant pulmonary disease * patients with lung lobectomy or lung volume reduction or lung transplantation * patients with α-1 antitrypsin deficiency * patients who have had live attenuated vaccinations within 30 days prior to screening visit or during run-in period other protocol-defined inclusion/exclusion criteria may apply.

Keywords: chronic obstructive pulmonary disease, nva 237, glycopyrronium, copd
randomized, double-blind study of efficacy and safety of bexotegrast (pln-74809) for idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: a randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (pln-74809) for the treatment of idiopathic pulmonary fibrosis (beacon-ipf).

this is a randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of 2 doses of bexotegrast (pln-74809) \[160 and 320 mg\] taken for 52 weeks by participants with ipf taking and not taking background therapy (ie, nintedanib or pirfenidone). the study will consist of an up to 35-day screening period, a 52-week treatment period, and a 14 day safety follow-up period. of note, participants who are not taking background therapy at study entry will be allowed to initiate it at any time during the study.

Eligibility criteria:
inclusion criteria: 1. ≥ 40 years of age prior to screening 2. ipf diagnosis ≤ 7 years prior to screening 3. fvcpp ≥ 45% 4. diffusing capacity for carbon monoxide percent predicted (hemoglobin-adjusted) ≥ 30% and \< 90% 5. current treatment for ipf with background therapy is allowed, if at a stable dose for ≥ 12 weeks prior to screening 6. if not currently receiving treatment for ipf (either treatment naïve or discontinued prior treatment), participant must not have taken background therapy for at least 8 weeks prior to screening exclusion criteria: 1. receiving pharmacologic therapy for pulmonary hypertension 2. self-reported smoking of any kind (not limited to tobacco) 3. history of malignancy within the past 5 years or ongoing malignancy other than basal cell carcinoma, resected noninvasive cutaneous squamous cell carcinoma, or treated cervical carcinoma in situ 4. hepatic impairment or end-stage liver disease 5. renal impairment or end-stage kidney disease requiring dialysis 6. pregnant or lactating female participant 7. uncontrolled systemic arterial hypertension 8. receiving any unapproved or investigational agent intended for treatment of fibrosis in ipf 9. prior administration of bexotegrast 10. likely to have lung transplantation during the study (being on transplantation list is not an exclusion) 11. forced expiratory volume in the first second (fev1)/fvc ratio \<0.7 at screening 12. clinical evidence of active infection, including, but not limited to bronchitis, pneumonia, or sinusitis that can affect fvc measurement during screening or at randomization 13. known acute ipf exacerbation, or suspicion by the investigator of such, 6 months prior to screening

Keywords: ipf idiopathic pulmonary fibrosis pulmonary fibrosis bexotegrast beacon beacon-ipf
a study of ly3113593 in participants with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: this study is not intended to treat anemia of chronic kidney disease but to determine the safety of the study drug, ly3113593. the study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has on the body. the study consists of up to three parts. participants may only enroll in one part. participants will receive up to four injections of ly3113593 or placebo into a vein. the study will last up to about 26 weeks including screening and follow-up.


Eligibility criteria:
inclusion criteria: * receiving hemodialysis regularly (at least 3 times per week) for at least 4 months * have a hemoglobin value (taken prior to dialysis, if taken on a dialysis day) greater than or equal to 9.5 grams per deciliter (g/dl) and less than or equal to 11.0 g/dl at screening * have been receiving erythropoiesis stimulating agent (esa) injections for at least 4 weeks and are willing to stop the injections for approximately 8 weeks exclusion criteria: * have another health condition that may put the participant at risk or that the study doctor feels would make the participant unsuitable for the study * currently taking part in another study * have recently (within 30 days) completed a study or have previously taken part in this study
analgesia iv vs epidural analgesia vs port-sites infiltration after laparoscopic sleeve gastrectomy

Conditions: Postoperative Pain

Summary: a prospective randomized study of patients undergoing laparoscopic sleeve gastrectomy between 2012 and 2015 will be performed. patients will be divided into 3 groups: analgesia iv exclusively (group 1), epidural analgesia+analgesia iv (group 2) and port-sites infiltration+analgesia iv (group 3). pain will be quantified by means of a visual analogic scale and morphine rescue needs were determined 24 hours after surgery.

a prospective randomized study of patients undergoing laparoscopic sleeve gastrectomy between 2012 and 2015 will be performed. patients will be randomized using a computerized simple randomization scheme in a 1:1:1 ratio into 3 groups: those patients receiving only intravenous analgesia (group 1), those ones receiving intravenous analgesia associated to epidural analgesia (group 2) and those patients receiving intravenous analgesia associated with port-sites infiltration with bupivacaine. pain quantification as measured by visual analogic scale (vas), ranging from 0 (absence of pain) to 10 (unbearable pain) will be evaluated 24 hours after surgery.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>40 kg/m2 * bmi \> 35 kg/m2 with the presence of comorbidities associated to obesity exclusion criteria: * patients undergoing other bariatric techniques * severe underlying cardiovascular diseases * chronic renal failure * hepatic dysfunction * previous foregut surgery * patients with any contraindication for bariatric surgery
the pandemic's effect on diagnosis and treatment of rectal cancer

Conditions: Rectal Cancer

Summary: colorectal cancer is common with an annual prevalence of 6000. the majority can be cured and the five year survival rate is over 60%. in december 2019 reports came in about sars-cov-2, which later was named covid-19. the world health organization classified it as a pandemic in march 2020. in sweden the number of patients with covid-19 increased mainly in the urban areas in march 2020. care for patients with other diseases were affected and local changes from guidelines were adopted. in some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. the number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. the true effect on outcome with a delayed diagnosis remains unknown. the aim of this study is to evaluate the effects of the covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.


Eligibility criteria:
inclusion criteria: * rectal cancer diagnosis 2019-2022 exclusion criteria: * no rectal cancer diagnosis 2019-2022
surgical treatment for patients with obstructive sleep apnea by using da vinci sp surgical system

Conditions: Obstructive Sleep Apnea

Summary: this prospective, interventional, non-randomized, single arm, clinical trial will investigate feasibility and safety of trans-oral robotic surgery using da vinci sp surgical system in taiwan for the surgical treatment of osa. all the investigators are well trained and have received proof of training after completing the training program for da vinci sp system provided by intuitive.

this study will be conducted in chang gung memorial hospital at linkou. informed consent will be provided to patient who has an indication of surgical treatment for osa. study participants will sign an informed consent before any study procedure begins. eligibilities will be assessed during screening period (2 weeks) with blood test and other routine assessments. eligible patient will undergo surgical intervention using da vinci sp surgical system. post-operation follow-up will be performed at 1 week, 1 month, 3 months, and 6 months.

Eligibility criteria:
inclusion criteria: 1. age 18 years or more. 2. osa with ahi ≥ 15 3. has failed, refuses, or is unable to tolerate cpap therapy 4. indication of resection of tongue base with/without other invasive surgical procedure for osa (i.e. tongue base resection only or multi-level surgery with tongue base resection) 5. asa physical status classification 1-2 and adequate organ function 6. patients willing and able to comply with study protocol requirements and follow-up 7. informed consent exclusion criteria: 1. bmi\>35 2. mouth opening too narrow for tors or trismus 3. betel nut chewing 4. suspicious cancer diagnosis 5. prior head-and-neck surgery (note: prior invasive therapy for osa allowed) 6. other medical condition or anatomical factor not suitable for tors, including subject with congenital malformations in the larynx, throat or tongue; 1. subject with an american society of anesthesiologists (asa) score of grade 4 or above during preoperative evaluation 7. active infectious disease 8. can't follow trial-required procedures 9. severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions * severe heart disease (nyha functional class iii-iv) * severe lung disease (gold group c-d) 10. long-term use of anti-coagulant 11. patients with coagulopathy 12. emergency surgery 13. subject for whom any additional surgeries are planned for osa within the study period, after the surgery in which the da vinci sp system was used 14. subject is pregnant or suspected to be pregnant
design and validation of a new assessment tool for lichen planopilaris

Conditions: Lichen Planopilaris of Scalp; Lichen Plano-Pilaris; Lichen Planopilaris; Frontal Fibrosing Alopecia

Summary: the study's primary objective is to design and validate a grading system for objective and accurate assessment of lichen planopilaris. secondary objectives: * to assess change in symptoms such as pain and itch using a numeric rating scale(nrs) scores and quality of life using the dermatology life quality index (dlqi) scores * to correlate this grading system with patient skin biopsies evaluating disease activity on a microscopic level * to correlate this grading system with digital global photography and trichoscopy


Eligibility criteria:
inclusion criteria: 1. male or female subjects in general good health between the ages of 18 and 80 years old 2. clinical and histologic diagnosis of lichen planopilaris 3. subject is able to understand and sign informed consent 4. subject is able to complete the study and comply with study procedures 5. subject has no known allergy to non-toxic ink 6. subjects should be managed by an massachusetts general hospital dermatologist for their lichen planopilaris for the duration of the study exclusion criteria: eligible subjects will be excluded from participation if they meet any of the following criteria: 1. presence of dermatoses that might interfere with lpp diagnosis and/or evaluation such as seborrheic dermatitis or psoriasis 2. other selected concomitant causes of hair loss, including discoid lupus erythematosus, central centrifugal cicatricial alopecia (ccca), telogen effluvium 3. abnormal tsh laboratory value \>1 standard deviation above normal within last year 4. any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment 5. any known allergy to non-toxic ink related to biopsy 6. history of poor wound healing or blood-clotting abnormality 7. history of keloid formation or hypertrophic scarring 8. regular intake of high doses of aspirin or anti-coagulant medications 9. hypersensitivity to local anesthetics 10. history of poorly controlled diabetes mellitus 11. pregnant, nursing or planning a pregnancy
efficacy of preoperative diclofenac potassium- acetaminophen combination on anesthetic success in patients with symptomatic irreversible pulpitis: a randomized controlled trial

Conditions: Symptomatic Irreversible Pulpitis

Summary: the purpose of this study is to assess the effect of preoperative a single-dose of 50 mg diclofenac potassium- 1000mg acetaminophen combination compared to diclofenac potassium alone or placebo on local anesthetic success and postoperative pain in patients with symptomatic irreversible pulpitis.

patients with moderate-to-severe preoperative pain are selected. patients receive either a single-dose of diclofenac potassium (50mg)- acetaminophen (1000mg) combination, diclofenac potassium (50mg) alone or a placebo tablet as a control. all patients will receive the assigned premedication one hour before single-visit root canal treatment. anesthetic success of inferior alveolar nerve block will be assessed during access and instrumentation. postoperative endodontic pain is measured at the following time points: 6,12,24,48,72h and 7 days after treatment.

Eligibility criteria:
inclusion criteria: * patients with symptomatic irreversible pulpitis with/without mechanical allodynia * patients with moderato to severe spontaneous pain * mandibular molars * patients with the ability to understand and use the pain scale * patients accepting enrollment in the study exclusion criteria: * patients allergic to any medication or material to be used in the study * pregnant and lactating females * patients taking medications affecting pain perception in the last 12 hours * patients having more than one symptomatic molar in the same quadrant * patients with contributory medical history (asa \> ii)
assessing the prevalence of attention deficit hyperactivity disorder (adhd) symptoms in undiagnosed young adults:a cross sectional study

Conditions: Finding the Prevalence of ADHD in Undiagnosed Young Adults

Summary: to asses the prevalence of attention deficit hyperactivity disrorder in undiagnosed young adults.

finding the prevalence of attention deficit hyperactivity disorder (adhd) in undiagnosed young adults using the questionnaire provided by who ,

Eligibility criteria:
inclusion criteria: * undiagnosed exclusion criteria: * diagnosed with any mental disability
study of maggot therapy in diabetic foot ulcers

Conditions: DIABETIC FOOT ULCERS

Summary: this study was a kind of clinical trial with equal randomization, that have been done from january 2009 to june 2011 in the afzalipoor hospital endocrine ward in kerman-iran on 128 diabetic patient who had foot wounds.replacement of conventional therapy by new methodes is one of the more important aims for health professional specially for nurses.one of this new treatment is maggot therapy.


Eligibility criteria:
inclusion criteria: * have a chronic illness more than 7 weeks. * the age of the patients between 40- 90 years old. * not having capillary disease (blockage of artery, rinold). * not user of anticoagulants and corticosteroids drugs. * patients without history of allergy to drugs and foods. * having diabetic type 2 exclusion criteria: * patients who refer to critical clinical care unit * patients who have amputation

Keywords: maggot therapy diabetic foot nursing care dressing